Skip to main content
. 2018 Sep 21;8(5):628–636. doi: 10.1002/cpdd.618

Figure 1.

Figure 1

Study design (A) and schedule of visits and assessments (B). Dose escalation to 6 g CSL112 was recommended following Data Safety and Monitoring Board review of data for the 2 g CSL112 dose. DSMB, Data and Safety Monitoring Board; Mod RI, moderate renal impairment; NRF, normal renal function; PD, pharmacodynamics; PK, pharmacokinetics.